• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Is Earnings Swing Altering The Investment Case For Nurix Therapeutics Stock (NRIX)?

    Simply Wall St·10/22/2026 21:32:42
    Listen to the news
    • Nurix Therapeutics reported third quarter 2026 revenue of US$673.06 million, net income of US$549.81 million and diluted EPS from continuing operations of US$4.73, compared with a loss and far lower revenue in the prior year period.
    • The nine month figures show US$688.36 million in revenue and US$373.1 million in net income, which suggests a heavy contribution from large collaboration or licensing payments rather than recurring product sales alone.
    • Now the focus shifts to how Nurix Therapeutics's investment narrative absorbs this sharp swing to profitability driven by third quarter earnings.

    Explore how Nurix Therapeutics fits into a broader range of potential opportunities by reviewing our curated list of 21 high quality undiscovered gems that may still be flying under most investors' radar.

    Nurix Therapeutics Investment Narrative Recap

    For Nurix Therapeutics, the core belief is that its degrader platform and partnered programs like bexobrutideg can turn strong early data into durable commercial products and ongoing collaboration income. The latest quarter shows what the business can look like when large partnership payments hit. The key near term catalyst is still clinical and regulatory progress across bexobrutideg indications rather than a single blowout quarter.

    The biggest operational risk is that these earnings prove episodic if future periods resemble earlier quarters with limited license inflows and high R&D spend. The Q3 2026 profit helps the balance sheet and gives more room to fund trials. It does not remove the risk that later stage bexobrutideg data or partner decisions fall short of current expectations.

    The earnings announcement for the third quarter to August 31, 2026 is the clearest recent data point to connect to Nurix Therapeutics catalysts. Revenue of US$673.06 million and net income of US$549.81 million highlight how concentrated economics can be when large collaboration payments are recognized. That scale of contribution intersects directly with the Roche bexobrutideg agreement and the broader partnership model.

    For you as a shareholder, the question is how often and how reliably such collaboration driven periods can occur alongside ongoing trial spend. The same announcement shows nine month revenue of US$688.36 million versus US$70.4 million a year earlier and a swing from a US$186.24 million loss to US$373.1 million of profit. That contrast underlines both the upside of the model and the risk of lumpiness if future milestones do not materialize on a similar timetable.

    Nurix Therapeutics' narrative projects US$297.9 million revenue and US$47.6 million earnings by 2029. This reflects a 24.9% yearly revenue decline and an earnings decrease of US$247.3 million from US$294.9 million today.

    Uncover how Nurix Therapeutics' fair value indicates a 33% potential upside to its current price before the market closes that gap.

    NasdaqGM:NRIX 1-Year Stock Price Chart
    NasdaqGM:NRIX 1-Year Stock Price Chart

    Exploring Other Perspectives

    Some bearish analysts focused on the risk that Nurix Therapeutics could remain loss making, even with partnerships. Before this earnings release, the lowest forecasts penciled in about US$54.6 million of 2029 revenue and only US$9.4 million of earnings. That is a far more cautious story. Use this jump in results to compare with your own view.

    Explore 2 other Nurix Therapeutics fair value estimates, including one that suggests it could be worth just $34.50!

    Form Your Own Verdict

    Don't just follow the ticker; dig into the data and build a conviction that's truly your own.

    Looking For More Investment Ideas Beyond Nurix Therapeutics?

    Once you have a handle on Nurix Therapeutics, it can help to compare it with other potential opportunities using the Simply Wall St Screener so you can stress test your thesis against different types of businesses and risk profiles.